Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0VI2M
|
|||
| Drug Name |
US10100051, Compound 11
|
|||
| Synonyms |
SCHEMBL18122076; BDBM292142; US10100051, Compound 11; 2-(2-(3-(tert-butyl)phenoxy)-5-hydroxy-8-methyl-1,7-naphthyridine-6-formamido) acetic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H23N3O5
|
|||
| Canonical SMILES |
CC1=C2C(=C(C(=N1)C(=O)NCC(=O)O)O)C=CC(=N2)OC3=CC=CC(=C3)C(C)(C)C
|
|||
| InChI |
1S/C22H23N3O5/c1-12-18-15(20(28)19(24-12)21(29)23-11-17(26)27)8-9-16(25-18)30-14-7-5-6-13(10-14)22(2,3)4/h5-10,28H,11H2,1-4H3,(H,23,29)(H,26,27)
|
|||
| InChIKey |
NYGCHYPUCCYURU-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HIF-prolyl hydroxylase 2 (HPH-2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | HIF-prolyl hydroxylase 2 (HPH-2) | Target's Patent Info | [1] | |
| KEGG Pathway | HIF-1 signaling pathway | |||
| Pathways in cancer | ||||
| Renal cell carcinoma | ||||
| Panther Pathway | Hypoxia response via HIF activation | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.